PK/PD Studies for Bladder Cancer Therapy
At Alfa Cytology, our expertise in pharmacokinetics (PK) and pharmacodynamics (PD) studies is instrumental in driving the development of novel bladder cancer therapeutics.
Introduction to PK/PD Studies
PK describes what the body does to a drug, while PD elucidates the drug's effects on the body - together, these fundamental principles provide a comprehensive understanding of a drug's behavior and its relationship with the desired clinical outcomes. In the context of bladder cancer, PK/PD studies play a critical role in optimizing drug dosing regimens, evaluating efficacy, and assessing safety.
Fig 1. The Role of PK/PD in Drug Development Process. (Zou H., et al. 2020)
By carefully characterizing the absorption, distribution, metabolism, and elimination of a candidate drug, our scientists can predict its exposure and concentration within the tumor microenvironment. Coupling this PK data with an assessment of the drug's pharmacodynamic effects, such as its impact on tumor growth, angiogenesis, or immune modulation, allows us to establish the PK/PD relationship and identify the optimal therapeutic window.
Our Services
At Alfa Cytology, our suite of PK/PD services is tailored to support bladder cancer drug development. Our experienced team of scientists leverages state-of-the-art analytical techniques, including liquid chromatography-mass spectrometry (LC-MS/MS) and advanced biomarker assays, to provide comprehensive PK/PD data.
Our services include but are not limited to:
| Our Services |
Descriptions |
| Ex Vivo Pharmacodynamic (PD) Services |
- Cytokine profiling (e.g., cytokine bead array, ELISA, Luminex)
- Receptor occupancy (flow cytometry-based)
- Immune cell profiling (flow cytometry, histology, immunofluorescence, immunohistochemistry)
- Target/biomarker expression (digital PCR, immunofluorescence, qPCR, RNA scope)
|
| Ex Vivo Pharmacokinetic (PK) Services |
- Dose range finding and maximum tolerated dose studies
- Drug administration via various routes (i.v., i.p., s.c., p.o., i.t., i.m.)
- Sample collection from blood, bone marrow, tumor, spleen, liver, and other tissues
- PK analysis of biotherapeutics using ELISA or MSD
- Bioavailability and biodistribution assessments
|
| In Vitro Pharmacology Services |
- Antibody-dependent cellular cytotoxicity (ADCC)
- Antibody-dependent cellular phagocytosis (ADCP)
- Complement-dependent cytotoxicity (CDC)
- Drug blocking assays
- Drug-cell binding assays
- Endocytosis
- Hemolysis and coagulation tests
- In vitro stimulation assays
- Mixed lymphocyte reaction (MLR)
|
| In Vivo PK/PD services |
- Pharmacokinetics (PK) Studies
- PK Sample Analysis
- Toxicokinetics (TK) Studies
- Metabolite Identification and Profiling
- Rapid PK Screening
- Mass Balance
- Tissue Distribution
- Bioequivalence (formulation support)
- MSD-ECLA (Meso Scale Discovery) Assays
- ELISA Assays
|
| Available Species |
- Mouse
- Rat
- Rabbit
- Guinea Pig
|
Contact Us
To learn more about how our PK/PD services can accelerate your bladder cancer drug development program, please don't hesitate to contact us. We are committed to collaborating with our clients to unlock the full therapeutic potential of novel compounds and advance the field of bladder cancer therapy.
Reference
- Zou H., Banerjee P., and et al. Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges. Front Pharmacol. 2020, 3, 11: 997.
For research use only. Not intended for any clinical use.
Related Services
